Shots:
AbbVie has reported the P-III (CERVINO) trial assessing etentamig (Q4W) vs standard available therapies in pts with R/R MM who have received ≥2 prior lines of therapy, incl. exposure to a proteasome inhibitor, an immunomodulatory drug & an anti-CD38 mAb
At the mFU of 11.4mos. (n=393 pts; median 3 prior lines), trial met its dual 1EPs…
